Targeting angiogenesis in oncology, ophthalmology and beyond
Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
Risk factors for progression of age‐related macular degeneration
TJ Heesterbeek, L Lorés‐Motta… - Ophthalmic and …, 2020 - Wiley Online Library
Purpose Age‐related macular degeneration (AMD) is a degenerative disease of the macula,
often leading to progressive vision loss. The rate of disease progression can vary among …
often leading to progressive vision loss. The rate of disease progression can vary among …
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
AM Khanani, SS Patel, G Staurenghi, R Tadayoni… - The Lancet, 2023 - thelancet.com
Background Geographic atrophy is an advanced form of dry age-related macular
degeneration that can lead to irreversible vision loss and high burden of disease. We aimed …
degeneration that can lead to irreversible vision loss and high burden of disease. We aimed …
[HTML][HTML] The diagnosis and treatment of age-related macular degeneration
A Stahl - Deutsches Ärzteblatt International, 2020 - ncbi.nlm.nih.gov
Background Age-related macular degeneration (AMD) is thought to cause approximately 9%
of all cases of blindness worldwide. In Germany, half of all cases of blindness and high …
of all cases of blindness worldwide. In Germany, half of all cases of blindness and high …
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
Abstract Background/Objectives To assess the safety and efficacy of avacincaptad pegol
(ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular …
(ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular …
Age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of legal blindness in the
industrialized world. AMD is characterized by accumulation of extracellular deposits, namely …
industrialized world. AMD is characterized by accumulation of extracellular deposits, namely …
[HTML][HTML] Global burden of dry age-related macular degeneration: a targeted literature review
NM Schultz, S Bhardwaj, C Barclay, L Gaspar… - Clinical …, 2021 - Elsevier
Purpose Age-related macular degeneration (AMD) is a leading cause of blindness,
particularly in higher-income countries. Although dry AMD accounts for 85% to 90% of AMD …
particularly in higher-income countries. Although dry AMD accounts for 85% to 90% of AMD …
[HTML][HTML] Progression from early/intermediate to advanced forms of age-related macular degeneration in a large UK cohort: rates and risk factors
U Chakravarthy, CC Bailey, PH Scanlon… - Ophthalmology …, 2020 - Elsevier
Purpose To estimate rates and risk factors for progression to geographic atrophy (GA) or
choroidal neovascularization (CNV) among eyes diagnosed with early or intermediate age …
choroidal neovascularization (CNV) among eyes diagnosed with early or intermediate age …
Age-related macular degeneration: epidemiology and clinical aspects
Age-related macular degeneration (AMD) is a degenerative disease of the human retina
affecting individuals over the age of 55 years. This heterogeneous condition arises from a …
affecting individuals over the age of 55 years. This heterogeneous condition arises from a …
[HTML][HTML] Endpoints for clinical trials in ophthalmology
With the identification of novel targets, the number of interventional clinical trials in
ophthalmology has increased. Visual acuity has for a long time been considered the gold …
ophthalmology has increased. Visual acuity has for a long time been considered the gold …